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Abstract.
Background:Use of antipsychotics in elderly patients with dementia has decreased in the past decade due to safety regulations;
however use is still high. Geographical variation may indicate discrepancies in clinical practice and lack of adherence to
evidence-based guidelines for the management of behavioral symptoms.
Objective: To investigate potential geographical variances in use of antipsychotic drugs in dementia care.
Methods: A registry-based cross-sectional study in the entire elderly population of Denmark (≥65 years) conducted in 2012.
Data included place of residence, prescriptions filled, and hospital discharge diagnoses. Antipsychotic drug use among elderly
with (n = 34,536) and without (n = 931,203) a dementia diagnosis was compared across the five regions and 98 municipalities
in Denmark, adjusted for age and sex.
Results: In 2012, the national prevalence of antipsychotic drug use was 20.7% for elderly patients with dementia, with a
national incidence of 3.9%. The prevalence ranged from 17.0% to 23.3% in the five regions and from 7.5% to 33.1% in the
98 municipalities, demonstrating an over four-fold difference.
Conclusion: The observed geographical variation was more pronounced at municipal level as compared to regional level,
suggesting that the variation may be related to variances in clinical practice in primary care. This study highlights an urgent
need for further educating professional carers and physicians to guide non-pharmacological as well as pharmacological
management of neuropsychiatric symptoms in elderly patients with dementia.
Keywords: Antipsychotic drugs, clinical practice variation, dementia, geography, small area variation
∗Correspondence to: Gunhild Waldemar, Professor, MD,
DMSc, Danish Dementia Research Centre, Department of Neu-
rology, Neuroscience Centre, Rigshospitalet, University of
Copenhagen, Blegdamsvej 9, #6922, 2100 Copenhagen Ø,
Denmark. Tel.: +45 3545 2580; E-mail: gunhild.waldemar.01@
regionh.dk.
INTRODUCTION
Antipsychotics are used for treatment of certain
neuropsychiatric symptoms in elderly patients with
dementia, e.g., agitation, aggression, and psychotic
symptoms [1]. However, the clinical effectiveness
of typical and atypical antipsychotic drugs on these
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symptoms in patients with dementia is question-
able [2–4]. The potential modest clinical effect of
antipsychotic treatment needs to be balanced against
numerous adverse events, including parkinsonian
side effects, sedation, gait disturbance, accelerated
cognitive decline, pneumonia and other infections,
and thromboembolic events [1, 5]. Antipsychotics
have also been associated with increased mortal-
ity risk [6], which has led the U.S. Food and Drug
Administration and the European Medicines Agency
to issue warnings in 2005 and 2008 regarding the
mortality risk associated with use of typical and atyp-
ical antipsychotics in elderly patients with dementia
[7, 8]. Best practice guidelines emphasize the need
for initial assessment and treatment of contributing
medical conditions, such as infections, dehydration
and pain, and non-pharmacological interventions as
first-line approach for management of behavioral
symptoms in patients with dementia, although short-
term treatment with antipsychotics may be warranted
in selected patients [9].
Following the warnings, some countries launched
initiatives to decrease the consumption of antipsy-
chotics. As a result, the use of antipsychotics in
elderly patients with dementia decreased in the past
decade. The NHS England national prescribing audit
showed a reduction in antipsychotic users from
17.0% in 2006 to 6.8% in 2011 in patients with
dementia of all ages [10]. Likewise, Scotland and
France demonstrated a similar decrease in use [11,
12]. In many other countries, use is still high [13–15].
In Denmark, use remains high despite a reduction
from 31.3% in 2000 to 20.4% in 2012 of antipsy-
chotic users with dementia ≥65 years of age [16].
The reasons for the high consumption of antipsy-
chotics in patients with dementia are unknown, but
the appropriateness of use has been questioned.
Geographical variation in the use of antipsychotics
may indicate discrepancies in clinical practice and
lack of adherence to evidence-based guidelines for
the management of behavioral symptoms. Thus,
geographical variation unexplained by other demo-
graphic or medical factors may indicate a mismatch
between clinical practice and clinical guidelines
in certain geographical areas. Danish registries are
unique with respect to capturing an entire population
and featuring detailed information on drug utiliza-
tion [17]. Knowledge about geographical differences
in the Danish population may provide further insight
into the extent and nature of variation in clinical prac-
tice in the care of neuropsychiatric symptoms in an
international context.
Thus, in order to determine possible factors con-
tributing to the relatively high consumption of
antipsychotics in Denmark, we aimed to investigate
potential geographical variation. Consequently, we
conducted a nationwide registry-based study in the
entire elderly population of Denmark, comparing
prevalence, incidence, and, duration of antipsychotic
treatment in elderly with and without a diagnosis of
dementia in 2012 between the Danish regions and
municipalities.
MATERIALS AND METHODS
Study design and ethics
The study was designed as an observational cross-
sectional study using data from nationwide Danish
registries.
The study was approved by the Danish Data
Protection Agency (ID no: 2007-58-0015/30-0667),
Statistics Denmark, and the Danish Health and
Medicine Authority (ID no: 6-8011-907/1). All
data were anonymized and Danish law did not
require ethic committee approval or informed patient
consent.
Registry data sources
All permanent residents are assigned a personal
civil registration number at the time of birth or immi-
gration [18], which allows for retrieval of data at an
individual level in nationwide registries [17]. The
National Patient Registry contains all hospitaliza-
tions and invasive procedures registered since 1977
and all contacts to outpatient clinics and emergency
departments since 1995 [19]. The Psychiatric Cen-
tral Research Registry includes data on all psychiatric
inpatient admissions since April 1, 1969, and outpa-
tient contacts since 1995 [20]. Information comprises
dates and discharge diagnosis, registered according
to World Health Organization’s (WHO) International
Classification of Diseases (ICD) codes. ICD-8 was
used from 1970 to 1993 and ICD-10 from 1994 and
onwards. The Danish National Prescription Registry
has registered dispensed prescriptions consecutively
since 1995, including prescriptions to elderly residing
in nursing homes. The drugs are registered according
to the Anatomical Therapeutic Chemical (ATC) clas-
sification system, with information on amount and
strength of dispensed drugs as well as dispensing
dates [21].
J.K. Zakarias et al. / Geographical Variation in Antipsychotic Use 1185
Demographic information
Denmark is divided into five regions and 98 munic-
ipalities. The regions are responsible for hospitals and
for private practice specialists and general practition-
ers (GPs). The municipalities are local administrative
bodies responsible for public healthcare, and for pri-
mary care including home care and nursing homes
for the elderly. Information about place of residence,
age, gender, and marital status was retrieved from
the Danish Civil Registration System, while infor-
mation on living status (nursing homes) was retrieved
from Statistics Denmark. Since the municipalities are
subunits of the regions, each individual in the study
population is both accounted for in the regional and
municipality analyses.
Study population
All Danish residents aged ≥65 years and alive on
January 1, 2012, were identified using the Central
Population Registry. The place of residence (region
and municipality) on January 1, 2012, was identified
using the Danish Civil Registration System. Patients
with a dementia diagnosis were identified as those
who had been registered with a dementia diagnosis
in the National Patient Registry or Psychiatric Cen-
tral Research Registry before January 1, 2012, during
admission or at an outpatient visit and/or those who
had filled an anti-dementia drug prescription (ATC:
N06D). The individuals had to be ≥60 years at the
time of the dementia diagnosis and/or first prescrip-
tion because the validity of the diagnosis in those <60
years has been shown to be low [22]. The validity of
registered dementia diagnoses in those ≥65 years,
in contrast, has previously been shown to be high
[23]. The remaining individuals formed the reference
group.
Antipsychotic treatment
Prevalent users of antipsychotic drugs were defined
as individuals who had at least one antipsychotic pre-
scription filled in 2012. Incident users were defined
as elderly who had their first ever antipsychotic
prescription filled in 2012 since 1995. Antipsy-
chotic drugs were classified according to ATC codes
(N05A), excluding lithium. Antipsychotic drugs were
assigned a defined daily dose (DDD), defined by
WHO as the average maintenance dose per day for
a drug used for its main indication in adults. As one
DDD represents one day of treatment, the number of
DDDs prescribed in 2012 was used as a marker for
treatment duration.
Comorbidity
Comorbidity was assessed at baseline (January 1,
2012). Data from somatic and psychiatric hospital
contacts was used to identify comorbid condi-
tions that could potentially influence antipsychotic
drug use. The Charlson comorbidity index com-
prises 19 chronic somatic diseases and was used
to assess comorbidity [24]. Psychiatric comorbidity
was defined as a registered diagnosis of prior psy-
chotic disorders [one of the following diagnoses:
schizophrenia, schizotypal, delusional disorders
(ICD-8:295.x9, 296.89, 297.x9, 298.29-298.29-
298.99, 299.04, 299.05, 299.09, 301.8; ICD-10: F20-
29); and, manic episode and bipolar affective disorder
(ICD-8:296.19, 296.39, 298.19; ICD-10: F30-F31)]
registered any time since 1969 before the dementia
diagnosis. The total number of different drugs used in
2011 was employed as a surrogate marker of somatic
disease not captured by hospital admissions (ATC
level 3, e.g., A10A: insulins and analogues).
Statistical analysis
Normality of continuous variables was graphi-
cally determined using histograms. The percentage of
antipsychotic users in the various regions was com-
pared using Pearson’s χ2-test and a Kruskal-Wallis
test for analysis of variance. Logistic regression
analyses were performed to evaluate the effect of indi-
vidual covariates (crude analysis) on the likelihood of
receiving an antipsychotic drug. A multivariate logis-
tic regression analysis was performed to control for
age, sex, and comorbidity, including Charlson comor-
bidity index, psychotic disorder prior to dementia
diagnosis, and total number of drugs used (adjusted
analysis). The percentage of antipsychotic users in
the various municipalities was adjusted using direct
standardization to account for differences in age
and sex between geographical areas. Furthermore, in
order to evaluate duration of use, the median num-
ber of DDD was calculated for each region and
compared using Pearson’s χ2-test and a Kruskal-
Wallis test for analysis of variance. A p-value of
<0.05 was considered statistically significant. The
data analysis was performed using SAS statisti-
cal software, version 9.3 (SAS Institute Inc., Cary,
NC, USA).
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RESULTS
Study population
On January 1, 2012, Denmark had 974,431 resi-
dents aged≥65 years. We excluded 2,341 individuals
because they had received a diagnosis of dementia
or anti-dementia drugs before the age of 60 years
and 6,351 individuals due to missing information on
place of residence. This resulted in a study popula-
tion of n = 965,739 individuals, n = 34,536 (3.6%) of
whom were classified with dementia and n = 931,203
(96.4%) who had not been registered with a demen-
tia diagnosis and formed the reference population
(Fig. 1). Table 1 presents the characteristics of the
study population stratified by dementia. The patients
classified with dementia were older, more likely to
be female, less likely to be married, more likely
to be a nursing home resident, and suffered from
comorbidity more frequently. Table 2 presents the
characteristics of the study population with demen-
tia stratified by region. Patients with dementia from
the Capital Region of Denmark differed from those
living in other regions in that they were older, less
likely to be married and had a higher incidence of
psychotic disorders prior to being registered with
dementia.
National prevalent and incident antipsychotic use
At the national level, prevalence of antipsychotic
users was 20.7% in elderly with dementia and
3.0% in elderly without dementia. The annual inci-
dence rate of antipsychotic users was 3.9% among
elderly with dementia and 0.7% among elderly
without dementia. Among patients with dementia
using antipsychotic drugs, 84.8% filled multiple pre-
scriptions. The median (25–75% interquartile range)
treatment duration was 42.0 DDD (20.0–90.0 DDD)
per antipsychotic user in elderly with dementia, and
33.0 DDD (13.8–100.0 DDD) in elderly without
dementia, indicating longer treatment duration in
patients with dementia (p < 0.05).
Prevalent and incident antipsychotic use
by region
Table 3 shows the use of antipsychotics in elderly
with dementia in the regions in 2012. The amount
of prevalent users varied from 17.0% in the Central
Denmark Region to 23.3% in the Capital Region of
Denmark. Incident antipsychotic users ranged from
Fig. 1. Population selection.
3.5% in the Central Denmark Region to 4.4% in the
Capital Region of Denmark. Table 4 presents the
results of a multivariate logistic regression analysis
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Table 1
Baseline characteristics in elderly with and without dementia
Characteristics Dementia (n = 34,536) Reference (n = 931,203)
Age, years 83.3 (77.6–88.1) 72.7 (68.3–79.1)
Female 64.9% 54.7%
Married 33.3% 56.6%
Nursing home resident 49.5% 3.1%
Charlson comorbidity index 2.0 (1.0–3.0) 0.0 (0.0–2.0)
Total number of drugs used 9.0 (6.0–12.0) 5.0 (3.0–9.0)
Time since dementia diagnosis, years 2.8 (1.3–5.2) NA
Psychotic disorder prior to dementia diagnosis 4.0% NA
Numbers are given as median (25–75% interquartile range) for data with a non-normal distribution. Frequency
numbers are given as percentage. NA, not applicable.
Table 2
Baseline characteristics of elderly patients with dementia in Denmark
Characteristics Regions
North Denmark Central Denmark Region of Southern Capital Region of Zealand Region
Region (n = 3,283) Region (n = 6,635) Denmark (n = 8,854) Denmark (n = 10,973) (n = 4,791)
Age, years 83.5 (77.7–87.8) 83.1 (77.8–87.7) 83.3 (77.7–87.9) 83.7 (77.8–88.6) 82.8 (77.0–87.8)
Female 64.9% 64.2% 64.1% 66.7% 63.5%
Married 35.1% 34.5% 35.2% 29.7% 34.8%
Nursing home resident 55.0% 51.0% 47.0% 50.4% 46.0%
Charlson comorbidity index 1.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0) 2.0 (1.0–3.0)
Total number of drugs used 9.0 (6.0–12.0) 9.0 (6.0–12.0) 9.0 (6.0–12.0) 9.0 (6.0–12.0) 8.0 (5.0–11.0)
Time since dementia diagnosis, 2.8 (1.2–5.1) 2.7 (1.2–4.9) 2.8 (1.3–5.2) 2.9 (1.3–5.3) 3.0 (1.4–5.4)
years
Psychotic disorder prior to 3.5% 3.4% 3.3% 5.1% 4.2%
dementia diagnosis
Numbers are given as median (25–75% interquartile range). Frequency numbers are given as percentage.
Table 3
Prevalent and incident use of antipsychotic drugs by regions in 2012
Dementia Regions
Total North Denmark Central Denmark Region of Southern Capital Region of Zealand Region
(n = 34,536) Region Region Denmark Denmark (n = 4,791)
(n = 3,283) (n = 6,635) (n = 8,854) (n = 10,973)
Prevalent antipsychotic 20.7% 18.9% 17.0% 21.6% 23.3% 19.7%
user
Incident antipsychotic 3.9% 3.8% 3.5% 3.7% 4.4% 3.8%
user
Treatment duration of 42.0 (20.0–90.0) 36.4 (15.0–91.0) 37.3 (18.2–86.1) 38.0 (18.8–75.6) 50.0 (24.0–101.5) 41.0 (15.4–91.0)
antipsychotics
(DDD∗)
Frequency numbers are given as percentage. ∗Treatment duration is given as median defined daily doses (DDD) (25–75% interquartile
range).
for the prevalence of antipsychotic users in elderly
patients with dementia stratified by region (with
the Central Denmark Region as the reference). All
other regions had a significantly higher prevalence
of antipsychotic users, also after adjustment for age,
sex, Charlson comorbidity index, psychotic disor-
der prior to dementia diagnosis, and total number of
drugs used.
Prevalent and incident use by municipality
The age and sex standardized antipsychotic use
in the 98 municipalities is listed in supplementary
Table 1 and shown in Fig. 2. The percentage of
antipsychotic users varied from 7.5% in Skander-
borg municipality to 33.1% in Vejen municipality,
demonstrating an over four-fold difference. Large
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Table 4
Probability of antipsychotic use in elderly with dementia across the five regions
Antipsychotic use
Crude OR Adjusted OR
Region
Capital Region of Denmark 1.42 (1.37–1.60) 1.70 (1.57–1.85)
Central Denmark Region 1 1
North Denmark Region 1.13 (1.02–1.26) 1.12 (1.01–1.25)
Zealand Region 1.20 (1.09–1.32) 1.36 (1.23–1.50)
Region of Southern Denmark 1.35 (1.24–1.46) 1.39 (1.28–1.51)
Odds ratio, OR; 95% confidence interval, 95% CI. Adjustment for age, gender, Charlson comor-
bidity index, psychotic disorder prior to dementia diagnosis, and total number of drugs used.
Fig. 2. Age and sex standardized prevalent use of antipsychotics in elderly patients with dementia by municipality. Samsø and Læsø
municipality were excluded due to insufficient amount of data (<10 antipsychotic users).
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differences between municipalities were present
within the same region as is evident, for example,
in the Central Denmark Region where the lowest
use was 7.5% (Skanderborg municipality) and the
highest use was 30.7% (Lemvig municipality), thus
demonstrating a four-fold difference.
DISCUSSION
In this study of the entire elderly population of
Denmark, the main finding was a pronounced geo-
graphical variation in the use of antipsychotics among
elderly patients with dementia that could not be
explained by variations in age and sex. The varia-
tion at the municipality level was prominent with an
over four-fold difference (from 7.5% to 33.1%) in
the prevalence of antipsychotic users, even between
municipalities within the same region (from 7.5% to
30.7%).
To our knowledge, this study is the first nation-
wide study analyzing geographical variation in use
of antipsychotics among patients with dementia. Pre-
vious studies have reported geographical differences
in use of antipsychotics, but aimed at investigating
the use in the general population or in patients with
schizophrenia [25–27]. In accordance with our study,
a study from the U.S. found local geographical varia-
tion in the use of antipsychotics that by far exceeded
the observed variability between states in the general
population of all ages [25]. These results may indi-
cate that the geographical variations are not limited to
patients with dementia. However, the study only cap-
tured 60% of all retail prescriptions in the population
and did not have individual-level data, which lim-
its the adjustment for characteristics/confounders and
generalizability of the results. Another U.S. study,
investigating antipsychotic users of all ages, found
that urban residents were 1.87 times more likely than
rural residents to use antipsychotic drugs [28]. The
present study did not investigate the impact of urban-
ization; however, the high prevalence of antipsychotic
users living in the urban Capital Region compared to
the low prevalence in the second largest urban area
(Aarhus) indicates that urbanization is not related to
treatment of antipsychotics in this study.
In our study, there was an over four-fold difference
at the municipal level, exceeding by far the more mod-
est differences between the larger regions. Hospitals
in Denmark are managed at a regional level. Thus,
differences at the regional level would indicate differ-
ences in hospital care. Since the use of antipsychotics
did not vary greatly at the regional level, it may indi-
cate that the observed geographical variation was
not primarily related to access to hospital care or to
dementia specialist departments. The variation was
pronounced between the 98 municipalities who are
responsible for public healthcare, and for primary
care including home care and nursing homes for the
elderly, indicating that variation may be related to
clinical practice in primary health care.
We may only speculate about the reasons for the
pronounced geographical variation. However, several
factors may play a role including local differences in
management strategies and care of patients with neu-
ropsychiatric symptoms, differences in knowledge or
attitude about antipsychotic treatment, and various
cultures in clinical practice.
In most cases, GPs are responsible for prescrip-
tion of medicine, although they may not have initiated
treatment. Antipsychotic drugs may be initiated in
somatic hospital departments for confusion, hal-
lucinations, or agitation related to acute physical
conditions and not discontinued prior to discharge.
Furthermore, it is possible that antipsychotic treat-
ment may be initiated based on initiative of family
or professional caregivers. In nursing homes, propos-
als for initiating antipsychotic treatment may arise
from clinical observations from the staff. A previ-
ous study in Danish nursing homes demonstrated
that clinical information of psychiatric morbidity pro-
vided by staff, and the recognition of neuropsychiatric
symptoms, is of great importance as their assessment
independently determined the use of psychotropic
treatment, including antipsychotics [29]. The study
indicated that antipsychotic drugs were used to treat
neuropsychiatric problems because they put an over-
whelming strain and workload on the staff [29]. A
qualitative study from the UK showed that psychia-
trists frequently felt pressured from nursing staff to
prescribemedications forneuropsychiatric symptoms
despite having knowledge of the limited clinical effect
and serious adverse effects [30]. The study also found
that the choice of medication was based on famil-
iarity, causing medications to vary greatly between
psychiatrists [30], thus suggesting that prescriptions
may be related to cultures in clinical practice. Fur-
thermore, psychiatrists also varied in monitoring the
effects of their prescribed medication [30], creating
the risk of long-term antipsychotic treatment occur-
ring. In an exploratory study from Belgium, GPs and
nurses, especially nurses with less education, showed
very low willingness to discontinue antipsychotics
in chronic antipsychotic users in nursing homes,
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indicating that current short-term antipsychotic users
are likely to become chronic users [31]. This mech-
anism is supported by this study’s finding of a low
proportion of incident users (3.9%) and the relatively
long, national average treatment duration of 42 DDD.
This is not in accordance with national guidelines,
which state that the treatment duration should not
exceed a week and if it does, treatment should be man-
aged by a psychiatrist [32]. International guidelines
also advise that treatment duration should be as short
as possible [33, 34]. Moreover, the actual treatment
duration in our population may be even longer than
42 days, as our data for treatment duration were based
on DDD of each type of antipsychotic drug defined by
WHO across all ages and indications. However, when
prescribed for patients with dementia, the usual daily
dose is often much lower, leading to an underestima-
tion of treatment duration in this study.
Differences in the composition of the study pop-
ulation and their disease patterns could potentially
play a role in the observed geographical differences in
antipsychotic consumption. In our study, all regions
had a significantly higher use of antipsychotics when
compared to the Central Denmark Region, even after
adjustment for age, sex, and comorbidity, including
Charlson comorbidity index, psychotic disorder to
dementia diagnosis and total number of drugs used.
Thus, it is our interpretation that the observed major
differences in the use of antipsychotics may be related
to cultures, attitudes, and lack of knowledge among
professional carers.
In support of this notion, the antipsychotic use
was shown to be low in the Central Denmark
Region, particularly in selected municipalities such as
Skanderborgmunicipality (7.5%) andAarhusmunic-
ipality (14.1%). The Central Denmark Region may
still be influenced by a leading old age psychiatrist
who established an old age psychiatry department
in 1987, aimed at lowering antipsychotic use among
elderly patients with dementia [35]. In accordance
with current guidelines, this restrictive approach to
treatment with antipsychotic drugs in elderly patients
with dementia may have had a long-term impact on
the cultures and attitudes in clinical practice in pri-
mary and secondary health care, thus resulting in the
observed low consumption in the area in 2012.
Our study indicates an overconsumption of
antipsychotics among patients with dementia due to
the large observed differences among the municipal-
ities. However, it should be emphasized that there
is no general agreement on a certain limit for accept-
able use, although our study suggests that the national
use could be reduced to a level below 10% as
demonstrated by the municipality with the lowest use
(Skanderborg municipality) and national data for the
UK [10]. Although this study was conducted in the
elderly population of Denmark, we believe that
the extent and nature of the observed differences in
the use of antipsychotics is also relevant in an inter-
national context. Other countries should be aware of
how cultures, attitudes, and knowledge about medical
treatment influence the management of neuropsychi-
atric symptoms in elderly patients with dementia and
could apply geographical differences in antipsychotic
prescriptions as quality indicators.
The main strength of this study is its nation-
wide population-based design and high reliability
of data linked by a unique personal identification
number, allowing investigation of the full spec-
trum of antipsychotic use in elderly patients with
dementia and adjustment for several important con-
founders such as age, sex, and comorbidity. Our
study investigated “real-life prescription patterns”
in an entire elderly population, thus avoiding prob-
lems of selection bias. Previous research has shown
that the validity of a dementia diagnosis in Danish
hospital registries is high in the elderly population
[23]. However, dementia is generally underdiagnosed
and potentially undiagnosed cases of dementia could
be included in the reference population. However,
baseline characteristics of the dementia population
were similar in the regions, so the underdiagnos-
ing of dementia could not explain the observed
geographical variation in antipsychotic treatment.
Data on prescriptions for antipsychotic drugs were
complete, but we did not have information about
indications and whether patients actually consumed
their prescriptions. However, 84.8% of patients
redeemed multiple prescriptions, suggesting that the
majority did consume the antipsychotics. Moreover,
although we had prescription data on the munici-
pality and regional levels, we did not have data on
who prescribed the antipsychotic treatment and we
can therefore only hypothesize on clinical practice
among professional carers and physicians in pri-
mary care as the driving force for the geographical
variation.
In conclusion, we found a pronounced geograph-
ical variation in the use of antipsychotics among
elderly patients with dementia in Denmark that could
not be explained by variations in age, sex, or comor-
bidity. The differences were more pronounced at
the municipality level, by far exceeding that of
the regional level, suggesting that the differences
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were primarily related to variances in clinical prac-
tice and care in primary care. Implementation of
guidelines for appropriate management of neuropsy-
chiatric symptoms is a challenging task that must
be addressed jointly by targeting multiple audiences
and not only the prescribing doctors. Future stud-
ies should explore potential consequences for patient
safety. Our study highlights an urgent need for more
education to guide non-pharmacological as well as
pharmacological management of neuropsychiatric
symptoms in elderly patients with dementia.
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